Search the Newsreel

GLUE|Monte Rosa Therapeutics Inc|Price:15.500|Chg%:-0.340

Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21%

Analysts have significantly upgraded Monte Rosa Therapeutics, Inc.'s revenue forecasts for 2026 by 21%, now expecting US$54m, an 87% increase from the prior year. Despite the increased revenue projections, the consensus price target has fallen by 18% to US$28.50, indicating that ongoing losses are …

Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update

Monte Rosa Therapeutics (GLUE) is under scrutiny after reporting increased Q2 net losses of US$43.4 million, leading to a 31.34% share price drop in the last month despite a strong 277.57% year-over-year return. The company, an early-stage biotech, currently trades at a high Price-to-Sales …

Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) recently reported Q2 results that fell short of revenue expectations, leading to increased losses. Despite this, analysts have upgraded 2026 revenue estimates while maintaining loss per share forecasts, indicating a brighter outlook for accelerated growth compared to the industry. …

What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders

Monte Rosa Therapeutics (GLUE) reported a widened net loss of US$43.4 million in Q2 2026, marking a significant shift from profit to deeper losses over six months. This financial performance highlights increased cost intensity, raising concerns about funding requirements and potential dilution risk for …

Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results

Monte Rosa Therapeutics (NASDAQ:GLUE) announced earnings results, reporting a loss of $0.43 per share, missing the consensus estimate of $0.38, and revenue of $8.97 million, below expectations of $12.91 million. Despite the miss, analysts maintain a "Moderate Buy" rating with an average price target …

The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE

The Manufacturers Life Insurance Company significantly increased its stake in Monte Rosa Therapeutics, Inc. by 55.8% in Q1, now holding over 209,801 shares valued at $3.45 million. Despite this, Monte Rosa Therapeutics reported weaker-than-expected Q1 results, missing both EPS and revenue estimates. Analysts maintain …

Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE

Dimensional Fund Advisors LP increased its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 83.2% in the first quarter, purchasing an additional 473,005 shares to own a total of 1.04 million shares, valued at $17.125 million. Other institutional investors also adjusted their positions in …

Monte Rosa Therapeutics (GLUE) Stock Faces Mounting Loss Pressure

Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo

Wells Fargo has reiterated its "Overweight" rating on Monte Rosa Therapeutics. This indicates the firm's positive outlook on the company's stock performance.

JPMorgan Chase & Co. Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price

Wells Fargo & Company Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00

Wells Fargo & Company has lowered its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) to $27.00 from $29.00, while maintaining an "overweight" rating. This adjustment comes despite the company missing quarterly earnings expectations, reporting a $0.43 per-share loss against an anticipated $0.38 loss and …

Monte Rosa Therapeutics: Q2 Earnings Snapshot

Monte Rosa Therapeutics Inc. (GLUE) reported a Q2 loss of $43.4 million, or 43 cents per share, missing analyst expectations of 25 cents per share. The biopharmaceutical company's revenue for the period was $9 million, also falling short of the $25.7 million anticipated by …

Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, Vs. FactSet Est of $12.9M

Monte Rosa Therapeutics, Inc. (GLUE) reported its Q2 collaboration revenue, which came in at $9.0 million. This figure was below FactSet's estimate of $12.9 million. The report provides key financial data for the quarter.

Monte Rosa Therapeutics, Inc. Stock 12‑Month Price Target Cut to $30.33, Implies 94% Upside

Monte Rosa Therapeutics, Inc. (GLUE) has seen its average 12-month price target reduced slightly from $30.67 to $30.33 by analysts, with a range between $25 and $37 per share. This updated target suggests a 94% potential upside from its Aug. 5 closing price. The …

Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal

Monte Rosa Therapeutics (GLUE) reported a significant deepening of Q2 2026 losses to US$43.4 million, up from US$12.3 million a year prior, and a reversal to a net loss of US$87.9 million for H1 2026 from a net income. This financial downturn has led …

Monte Rosa Therapeutics (NASDAQ: GLUE) posts 2026 net loss on revenue drop

Monte Rosa Therapeutics reported a significant net loss and a sharp drop in collaboration revenue for Q2 2026 and the first half of 2026. This decline was primarily due to the full recognition of a large Novartis upfront payment in 2025. Despite increased R&D …

Press Release: Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Monte Rosa Therapeutics has announced its financial results for the second quarter of 2026, along with key business updates. The company is providing an overview of its financial performance and strategic advancements during this period.

Monte Rosa Therapeutics earnings missed by $0.05, revenue fell short of estimates

Monte Rosa Therapeutics (NASDAQ: GLUE) reported second-quarter earnings per share of $-0.43, missing analyst estimates by $0.05. The company's revenue of $8.97 million also fell short of the consensus estimate of $12.91 million. Despite the recent earnings miss, the stock has shown significant growth, …

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) reported a Q2 loss of $0.43 per share, missing the Zacks Consensus Estimate of a $0.25 loss, and significantly missed revenue estimates with $8.97 million against a $23.19 million year-ago figure. The company's shares have underperformed the S&P 500 year-to-date, …

Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold"

Zacks Research has upgraded Monte Rosa Therapeutics (NASDAQ:GLUE) from a "strong sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with a $30.67 price target. The company recently reported a larger-than-expected quarterly loss of $0.43 per share and revenue …

Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029

Monte Rosa Therapeutics reported a net loss of $43.4 million for Q2 2026, with collaboration revenue reaching $9.0 million. The company's cash position of $626.0 million as of June 30, 2026, is expected to fund operations into 2029. Key business highlights include progress on …

Renaissance Technologies LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE

Renaissance Technologies LLC has made a new investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), purchasing 379,100 shares valued at approximately $6.2 million. This move comes despite the company reporting weaker-than-expected quarterly results and recent insider stock sales. Analysts currently maintain a "Moderate Buy" consensus …

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 4.1% After Analyst Downgrade

Monte Rosa Therapeutics (NASDAQ:GLUE) shares dropped 4.1% following a Wedbush downgrade, which cut the price target from $37 to $27 while maintaining an outperform rating. The company reported a wider-than-expected quarterly loss of $0.45 per share and significantly missed revenue estimates, posting $4.21 million …

Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $27.00 at Wedbush

Wedbush has lowered its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) to $27.00 from $37.00, while maintaining an "outperform" rating, indicating a potential 63% upside. The adjustment follows Monte Rosa's weaker-than-expected quarterly results, which included a larger-than-anticipated loss per share and lower revenue. Despite …

Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating

Wedbush has revised its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) to $27, down from the previous $37, while reaffirming an Outperform rating. This adjustment reflects a change in the analyst's valuation of the company's prospects.

Arrowstreet Capital Limited Partnership Acquires 340,088 Shares of Monte Rosa Therapeutics, Inc. $GLUE

Arrowstreet Capital Limited Partnership significantly increased its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 110.5% in the first quarter, now holding 647,739 shares. Despite this strong institutional interest and a "Moderate Buy" consensus from analysts, the company reported weaker-than-expected Q1 earnings, missing revenue …

Swiss National Bank Invests $1 Million in Monte Rosa Therapeutics, Inc. $GLUE

The Swiss National Bank has acquired a new stake of 61,100 shares, valued at $1.005 million, in Monte Rosa Therapeutics ($GLUE) during the first quarter. This investment is part of broader institutional interest, with institutional investors now owning nearly 80% of the company despite …

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down - Should You Sell?

Monte Rosa Therapeutics (NASDAQ:GLUE) experienced a significant share price drop of 29.4% after opening at $15.47, down from its prior close of $22.68, following a missed earnings report. The company reported a quarterly loss worse than expected and revenue significantly below estimates. Despite this, …

Why Monte Rosa Therapeutics (GLUE) Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its Goal

Monte Rosa Therapeutics (GLUE) saw its stock price drop by 27.5% after Novo Nordisk's ZEUS trial for an anti-inflammatory drug failed to meet its primary goal, impacting investor confidence in the broader inflammation-focused drug market. This setback has intensified scrutiny on Monte Rosa's scientific …

Why is Monte Rosa Therapeutics stock plunging today?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Recommendation of "Moderate Buy" by Analysts

Monte Rosa Therapeutics (NASDAQ:GLUE) has received a "Moderate Buy" consensus recommendation from analysts, with seven rating it a buy and two a sell. The average 12-month price target is $34.83, significantly above its $21.52 opening price. Despite this, the company reported a larger-than-expected quarterly …

Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday

Monte Rosa Therapeutics (GLUE) is set to release its Q2 2026 earnings before market open on Thursday, August 6th, with analysts forecasting a loss of $0.3657 per share and revenue of $12.9 million. The company missed expectations in the previous quarter, and its stock …